Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2907
Source ID: NCT04917692
Associated Drug: Empagliflozin
Title: Empagliflozin in Adolescent Diabetes
Acronym:
Status: WITHDRAWN
Study Results: NO
Results:
Conditions: type1diabetes
Interventions: DRUG: Empagliflozin
Outcome Measures: Primary: Interleukin 6, IL6 levels will be measured before and after high carbohydrate meal at the beginning and end of the 8 weeks, 8 weeks|Glomerular filtration rate, Cystatin C levels will be used to calculate GFR before and after high carbohydrate meal at the beginning and end of the 8 weeks, 8 weeks|Endothelial function, Percentage change in forearm vascular resistance following 5 min of arterial occlusion., 8 weeks|Number of episodes of diabetic ketoacidosis per patient, Frequency of diabetic ketoacidosis will be assessed through the 8 weeks, 8 weeks | Secondary: Complement, Complement component C3 and C4 levels will be measured before and after high carbohydrate meal at the beginning and end of the 8 weeks, 8 weeks|Lipids, Lipid levels will be measured before and after high carbohydrate meal at the beginning and end of the 8 weeks, 8 weeks|Pulse wave velocity, Pulse wave velocity will be measured before and after high carbohydrate meal at the beginning and end of the 8 weeks, 8 weeks|Number of episodes of hypoglycemia per patient, Frequency of hypoglycemia will be assessed over 8 weeks, 8 weeks
Sponsor/Collaborators: Sponsor: Ohio State University | Collaborators: Diacomp
Gender: ALL
Age: CHILD, ADULT
Phases: PHASE4
Enrollment: 0
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2021-07
Completion Date: 2022-10
Results First Posted:
Last Update Posted: 2023-03-23
Locations: Ohio State University, Columbus, Ohio, 43210, United States
URL: https://clinicaltrials.gov/show/NCT04917692